The North American company Da Vita, a leader in renal care medical services of high clinical quality and medical innovation with 20 years of experience, reaffirms its interest in entering Panama and prepares to resubmit its bid when the Social Security Fund (CSS) opens a new bidding process.
The company reported that its plan to establish its third operation in a Latin American country in Panama is solid, which will allow Panamanians with kidney problems to receive clinical care with the highest quality standards in the world market.
All of DaVita’s equipment is recognized by the United States Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA), making it successful in 12 countries, including the United Kingdom, Germany, Poland, China, Japan, Singapore , Malaysia, Saudi Arabia, Brazil and Colombia.
DaVita is considered one of the most financially strong companies in the healthcare sector in the United States of America and is listed on the New York Stock Exchange with a capitalization margin of $6.8 billion and consolidated revenues of $11.6 billion at the end of 2022.
DaVita maintains a very strict corporate code of conduct based on the US Foreign Corrupt Practices Act, as well as other anti-corruption and anti-bribery laws, including those prohibiting commercial bribery.
This places the company in a prominent position in the field of transparency and corporate governance standards.
DaVita representatives claim that Panamanian and kidney patients will have all this support, experience with excellent results and the possibility of accessing the latest technology on the market.
“Our interest goes beyond simply winning this public act, if not being faithful to our vision and mission as a company, and we are confident that we will have the opportunity to provide comprehensive care to kidney patients in Panama, in accordance with the strictest quality and safety standards, providing the best equipment, supplies , extras and personalized attention,” the company said.
DaVita has a successful clinical and operational track record that includes more than 65,000 associate specialists, more than 250,000 patients worldwide, 35 million life-saving treatments and 60 million laboratory results annually.
Internationally, DaVita operates 352 dialysis units in 12 countries where it is present; and its international operating center outside the United States is located in London, United Kingdom.
In Latin America, the company is present in Brazil and Colombia, and soon expects to enter the Panamanian market in order to ensure the highest standards of renal healthcare from the public system.
Representatives of the transnational company asserted that the model of care applied by all its services focuses on the care of patients in all conditions and situations, through a high-quality kidney healthcare strategy.
DaVita also clarified that the equipment it puts into use in its operations is guaranteed and of high quality, noting that it is approved by the FDA and/or EMA.
For this reason, the company emphasized that it works with all recognized brands on the market, as long as they comply with the safety specifications issued by the two most important health regulators in the world.
By working with different brands, DaVita says this allows it to match the most compatible provider to the different conditions and contexts of each operation or country, in order to provide the best possible care to each patient, regardless of the territory in which the company serves.
On March 23, the Social Security Fund (CSS) of Panama held a tender for the contracting of hemodialysis services for 7 years and the construction of 5 new hemodialysis units, with a reference price of 180 million dollars.
The Renal DVA – Sintec consortium, led by DaVita, together with Singularity Tech Pharma Corp. and Constructora Nova SA of Panama, presented an aggressive economic offer and met the requirements, according to the evaluation committee of the process.
However, HSS, referring to issues of public order and public interest, decided to suspend the contracting process and announced the announcement of a new tender.
The Renal DVA Consortium has decided not to appeal the CSS’s decision to allow the call for a new bidding process to be delayed and to re-engage with a competitive bid for the benefit of renal patients in Panama.
Source: Panama America
I am Jason Root, author with 24 Instant News. I specialize in the Economy section, and have been writing for this sector for the past three years. My work focuses on the latest economic developments around the world and how these developments impact businesses and people’s lives. I also write about current trends in economics, business strategies and investments.
